Systemic cyclosporine and corneal transplantation

International Ophthalmology

Volumn 36, Issue 1, 2016, Pages 139-146

  Ziaei, Mohammed ^a   Ziaei, Fatemeh ^b   Manzouri, Bita ^c  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b ROYAL OLDHAM HOSPITAL   (United Kingdom)

^c QUEEN S HOSPITAL   (United Kingdom)

Author keywords

Corneal transplantation; Cyclosporine; Immunosuppression; Keratoplasty; Rejection

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; CLINICAL EFFECTIVENESS; CONJUNCTIVITIS; CORNEA TRANSPLANTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; EYELID ERYTHEMA; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; REVIEW; SURVIVAL RATE; VISUAL DISORDER; VISUAL HALLUCINATION; PROCEDURES;

CORNEAL TRANSPLANTATION; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84955725878     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-015-0137-8     Document Type: Review

References (89)

1. The collaborative corneal transplantation studies (CCTS) (1992) Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol 110(10):1392–1403
2. Bradley BA et al (1993) Penetrating keratoplasty in the United Kingdom: an interim analysis of the corneal transplant follow-up study. Clin Transpl 293–315
3. Williams KA et al (2006) The Australian corneal graft registry 2004 annual report. http://hdl.handle.net/2328/1002
4. Hill JC (2002) High risk corneal grafting. Br J Ophthalmol 86(9):945
5. Khodadoust AA (1973) The allograft rejection reaction: the leading cause of late failure of clinical corneal grafts. In: Corneal graft failure. Ciba Foundation Symposium 15, new series. Elsevier. pp. 151–67
6. Report of the organ transplant panel (1988) Corneal transplantation. Council on scientific affairs. JAMA 259(5):719–722
7. Hoffmann F, Wiederholt M (1985) Local treatment of corneal transplants in the human with cyclosporin A. Klin Monbl Augenheilkd 187(2):92–96
8. Borel JF et al (1976) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6(4):468–475
9. European Multicentre Trial Group (1983) Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 2(8357):986–989
10. Calne RY et al (1979) Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2(8151):1033–1036
11. Claerhout I et al (2001) The effect of duration and timing of systemic cyclosporine therapy on corneal allograft survival in a rat model. Graefes Arch Clin Exp Ophthalmol 239(2):152–157
12. Nussenblatt RB, Palestine AG (1986) Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 31(3):159–169
13. Hoffmann F, Wiederholt M (1986) Topical cyclosporin A in the treatment of corneal graft reaction. Cornea 5(3):129
14. Kahan BD (1989) Cyclosporine. N Engl J Med 321(25):1725–1738
15. Belin MW, Bouchard CS, Phillips TM (1990) Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea 9(3):184–195
16. Petcher TJ, Weber H, Ruegger A (1976) Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv Chim Acta 59(5):1480–1489
17. Perry HD, Donnenfeld ED (2004) Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5(10):2099–2107
18. Pleyer U et al (1994) Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Curr Eye Res 13(3):177–181
19. Pleyer U et al (1993) Verteilung von Cyclophilin in okulären Geweben. Ophthalmologe 90:118
20. Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14(6):290–295
21. Fruman DA et al (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 89(9):3686–3690
22. Halloran PF, Kung L, Noujaim J (1998) Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 30(5):2167–2170
23. Horsley V, Pavlath GK (2002) NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 156(5):771–774
24. Waldmeier PC et al (2003) Cyclophilin D as a drug target. Curr Med Chem 10(16):1485–1506
25. Foulks GN (2006) Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 46(4):105–122
26. Avunduk AM et al (2003) The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 136(4):593–602
27. Maguire MG et al (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 101(9):1536–1547
28. Newton C, Gebhardt BM, Kaufman HE (1988) Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 29(2):208–215
29. Yoon KC et al (2008) Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model. Cornea 27(4):454–460
30. Rao SN (2006) Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 141(4):771–772
31. Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant 2012:230386
32. Scheer S et al (2003) Immunosuppression in corneal transplantation. J Fr Ophtalmol 26(6):637–647
33. Bertelmann E, Jaroszewski J, Pleyer U (2002) Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica 216(1):2–12
34. Wood AJ et al (1983) Cyclosporine: pharmacokinetics, metabolism, and drug interactions. Transplant Proc 15:2409–2414
35. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508
36. Hesselink DA, Bouamar R, van Gelder T (2010) The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 32(4):387–393
37. de Smet MD, Nussenblatt RB (1993) Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin 33(4):31–45
38. Keown P, Stiller C, Sinclair NR et al (1983) The clinical relevance of cyclosporine blood levels as measured by radioimmunoassay. Transplant Proc 15:2438–2441
39. Theng J et al (2002) Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther 18(1):83–88
40. Panda A et al (2007) Corneal graft rejection. Surv Ophthalmol 52(4):375–396
41. Mihatsch MJ, Thiel G, Ryffel B (1988) Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20(3 Suppl 3):759–771
42. Munoz SJ et al (1988) Elevated arterial blood pressure in survivors of liver transplantation treated with cyclosporine and corticosteroids. Transplant Proc 20(3 Suppl 3):623–627
43. Vine W et al (1988) Cyclosporine-induced hepatotoxicity: a microassay by hepatocytes in tissue culture. Transplant Proc 20(3 Suppl 3):859–862
44. Boubenider S et al (1997) Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 10(3):136–145
45. Kashani S, Mearza AA (2008) Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf 7(1):79–89
46. Rumelt S et al (2002) Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 86(9):988–992
47. Zimmerman TJ (1977) Textbook of ocular pharmacology. Lippincott-Raven, Washington
48. Lee JJ, Kim MK, Wee WR (2015) Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty. Graefes Arch Clin Exp Ophthalmol 253(7):1111–1119
49. Milani JK et al (1993) Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 100(6):890–896
50. Gebhardt BM, Varnell ED, Kaufman HE (1995) Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J Ocul Pharmacol Ther 11(4):509–517
51. Mahlberg K et al (1991) Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields. Graefes Arch Clin Exp Ophthalmol 229(1):69–74
52. Chen YF et al (1990) Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 109(2):132–137
53. Apel A et al (1995) A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Curr Eye Res 14(8):659–667
54. Lee SS et al (2007) A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci 48(5):2023–2029
55. Theng JT et al (2003) Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest Ophthalmol Vis Sci 44(11):4895–4899
56. Jaffe GJ et al (1998) Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 105(1):46–56
57. Pearson PA et al (1996) Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol 114(3):311–317
58. Salisbury JD, Gebhardt BM (1981) Suppression of corneal allograft rejection by cyclosporin A. Arch Ophthalmol 99(9):1640–1643
59. Wakefield D, McCluskey P (1991) Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol 7(3):221–226
60. Herbort CP et al (1989) Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection. Jpn J Ophthalmol 33(2):212–220
61. Coster DJ et al (1979) Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet 2(8144):688–689
62. Hunter PA et al (1982) Corneal graft rejection: a new rabbit model and cyclosporin-A. Br J Ophthalmol 66(5):292–302
63. Hill JC (1986) The use of systemic cyclosporin a in human corneal transplantation: a preliminary report. Doc Ophthalmol 62(4):337–344
64. Hill JC (1989) The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 107(5):506–510
65. Volker-Dieben HJ, D’Amaro J, Van Slooten H et al (1995) The effect of cyclosporin A on corneal graft survival. In: Zieruth M (ed) Immunology of corneal transplantation, 9th edn. Aeolus Press, Buren
66. Sundmacher R, Reinhard T, Heering P (1992) Six years’ experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study. Ger J Ophthalmol 1(6):432–436
67. Maeda N, Hosotani H, Ikeda T et al (1992) Effect of oral cyclosporine in high-risk corneal transplantation. Jpn J Clin Ophthalmol 46(1):1071–6
68. Yamagami S, OhyaT Tsuru T et al (1994) Effect of cyclosporine following penetrating keratoplasty. Jpn J Clin Ophthalmol 48:763–767
69. Hill JC (1994) Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 101(1):128–133
70. Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond) 9(Pt 4):422–428
71. Miller K et al (1988) Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation 45(3):651–653
72. Rossa V, Sundmacher R, Heering P (1990) Preventive systemic cyclosporin A in risk keratoplasty. Klin Monbl Augenheilkd 197(6):466–469
73. Reinhard T, Sundmacher R, Heering P (1996) Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 234(Suppl 1):S115–S121
74. Reinhard T et al (1997) Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. Ophthalmologe 94(7):496–500
75. Poon AC et al (2001) Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 85(12):1464–1469
76. Inoue K et al (2000) Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 44(3):302–305
77. Robert PY et al (1997) Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases. J Fr Ophtalmol 20(7):507–514
78. Shimazaki J et al (2011) Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 152(1):33–39 e1
79. Homan WP et al (1980) Effect of cyclosporin A upon second-set rejection of rat renal allografts. Transplantation 30(5):354–357
80. Gratwohl A, Forster I, Speck B (1981) Skin grafts in rabbits with cyclosporin A: absence of induction of tolerance and untoward side effects. Transplantation 31(2):136–138
81. Hess AD, Esa AH, Colombani PM (1988) Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 20(2 Suppl 2):29–40
82. Young AL et al (2002) Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye (Lond) 16(3):304–308
83. Lam DS et al (1998) The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: a preliminary study. Eye (Lond) 12(Pt 4):615–618
84. Margreiter R et al (1984) Cyclosporine in the treatment of acute allograft rejection refractory to high-dose methylprednisolone: results of a prospectively randomized trial. Transplant Proc 16(5):1202–1204
85. Wilson SE, Kaufman HE (1990) Graft failure after penetrating keratoplasty. Surv Ophthalmol 34(5):325–356
86. Donnenfeld E, Pflugfelder SC (2009) Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 54(3):321–338
87. Koay PY, Lee WH, Figueiredo FC (2005) Opinions on risk factors and management of corneal graft rejection in the United kingdom. Cornea 24(3):292–296
88. Bouchard CS, Cavanagh HD (1994) The high-risk keratoplasty patient–quo vadis? Cornea 13(1):1–3
89. McDonnell PJ et al (2003) Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol 121(11):1577–1581